Medicare chief: 'Door is really open' on Alzheimer's drugs coverage

Medicare is willing to reevaluate its coverage of Alzheimer’s drugs in light of a new therapy, called lecanemab, the CMS director said.

Related Keywords

,Centers For Medicare ,Milken Institute Future Of Health Summit ,Medicaid Services ,Milken Institute Future ,Health Summit ,